Quarterly report [Sections 13 or 15(d)]

Revenue Recognition

v3.25.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Recognition

3.

Revenue Recognition

Revenue by Service Line

 

Three Months Ended September 30,

 

(in thousands)

 

2025

 

 

2024

 

Biologics and drug delivery

 

 

 

 

 

 

Disposable products

 

$

1,292

 

 

$

2,062

 

Services and license fees

 

 

3,110

 

 

 

2,369

 

Subtotal – Biologics and drug delivery revenue

 

 

4,402

 

 

 

4,431

 

Neurosurgery navigation and therapy

 

 

 

 

 

 

Disposable products

 

 

3,422

 

 

 

2,860

 

Subtotal – Neurosurgery navigation and therapy revenue

 

 

3,422

 

 

 

2,860

 

Capital equipment and software

 

 

 

 

 

 

Systems and software products

 

 

647

 

 

 

552

 

Services

 

 

390

 

 

 

279

 

Subtotal – Capital equipment and software revenue

 

 

1,037

 

 

 

831

 

Total revenue

 

$

8,861

 

 

$

8,122

 

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2025

 

 

2024

 

Biologics and drug delivery

 

 

 

 

 

 

Disposable products

 

$

4,943

 

 

$

4,286

 

Services and license fees

 

 

8,889

 

 

 

8,779

 

Subtotal – Biologics and drug delivery revenue

 

 

13,832

 

 

 

13,065

 

Neurosurgery navigation and therapy

 

 

 

 

 

 

Disposable products

 

 

10,131

 

 

 

7,373

 

Subtotal – Neurosurgery navigation and therapy revenue

 

 

10,131

 

 

 

7,373

 

Capital equipment and software

 

 

 

 

 

 

Systems and software products

 

 

1,575

 

 

 

2,394

 

Services

 

 

1,023

 

 

 

787

 

Subtotal – Capital equipment and software revenue

 

 

2,598

 

 

 

3,181

 

Total revenue

 

$

26,561

 

 

$

23,619

 

Contract Balances

•
Contract assets – The timing of revenue recognition may differ from the time of billing to the Company's customers. In most cases, customers are billed upon shipment of such products or delivery of such services and the related contract assets, which represent an unconditional right to consideration, comprise the accounts receivable balance. When revenue is recognized in advance of its right to bill and receive consideration, the Company records this unbilled receivable as a contract asset, which is classified as other current assets in the accompanying condensed consolidated balance sheets.

(in thousands)

 

September 30, 2025

 

 

December 31, 2024

 

Accounts receivable, net

 

$

4,000

 

 

$

4,713

 

Other contract assets

 

 

 

 

 

 

Unbilled receivables

 

$

1,256

 

 

$

642

 
•
Contract liabilities – Contract liabilities consist of amounts that have been invoiced and for which the Company has the right to bill, but that have not been recognized as revenue as the related goods or services have not been transferred. The Company's contract liabilities are generally comprised of the following: (1) capital equipment and software-related service fees that are typically billed and collected at the inception of the service agreements, which have terms ranging from one to three years; (2) annual fees for agreements with customers that bundle the capital equipment and software-related service fees with software and hardware upgrades that are made commercially available over the term of the contract; and (3) up-front payments from customers made in connection with consulting services. The unearned portion of all such fees is classified as contract liabilities.

(in thousands)

 

September 30, 2025

 

 

December 31, 2024

 

Contract liabilities

 

$

2,488

 

 

$

2,557

 

During the three and nine months ended September 30, 2025, the Company recognized approximately $0.2 million and $1.2 million of revenue, respectively, which was previously included in contract liabilities in the accompanying condensed consolidated balance sheet at December 31, 2024. During the three and nine months ended September 30, 2024, the Company recognized approximately $0.2 million and $2.2 million of revenue, respectively, which was previously included in contract liabilities in the accompanying condensed consolidated balance sheet at December 31, 2023.

Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes contract liabilities that will be recognized as revenue in future periods. The majority of the remaining performance obligations relate to capital equipment and software-related service agreements and the upfront payments discussed under the heading "Contract Balances" above, which amounted to approximately $2.3 million at September 30, 2025. The Company expects to recognize 66% of this revenue over the next twelve months and the remainder thereafter.